CANADIAN CONSENSUS GUIDELINES
FOR THE TREATMENT OF
SEASONAL AFFECTIVE DISORDER
Canadian Consensus Guidelines for the Treatment of Seasonal Affective Disorder

Edited by
Raymond W. Lam, MD, FRCPC
Anthony J. Levitt, MBBS, FRCPC

On Behalf of the Canadian Consensus Group on SAD:
Carl Blashko, University of Alberta; Rudradeo C. Bowen, University of Saskatchewan; Murray Enns, University of Manitoba; A.-Missagh Ghadirian, McGill University; Christopher P. Gorman, University of Calgary; Gary Hasey, McMaster University; Robert P. Kraus, University of Western Ontario; Robert D. Levitan, University of Toronto; Rachel L. Morehouse, Dalhousie University; Adam Moscovitch, Canadian Sleep Institute, Calgary; Edwin M. Tam, University of British Columbia

External Consultant:
Dan Oren, Yale University

External Reviewers:
Michael Terman, Columbia University
Anna Wirz-Justice, University of Basel
CANADIAN CONSENSUS GUIDELINES FOR THE TREATMENT OF SEASONAL AFFECTIVE DISORDER

Edited by Raymond W. Lam, MD, FRCPC, and Anthony J. Levitt, MBBS, FRCPC
CONTENTS

Contributors / 9

Abbreviations Used / 11

Preface / 13
Dan A. Oren

Introduction / 17
Raymond W. Lam and Anthony J. Levitt

Section 1: Diagnosis, Epidemiology, and Pathophysiology / 20
(edited by Anthony J. Levitt)
Murray W. Emns, Robert D. Levitan, Anthony J. Levitt,
Elizabeth J. Dalton, and Raymond W. Lam

Part 1: Diagnosis / 20
How should a “seasonal pattern” of depression be defined? / 20
Table 1: Comparison of diagnostic criteria for SAD/seasonal pattern / 21
What are the usual symptoms of depression in SAD? / 23
Table 2: DSM-IV criteria for major depressive disorder with a seasonal pattern (equivalent to seasonal affective disorder) / 24
Is the diagnosis of SAD stable over time? / 25
What instruments are useful for the diagnosis and measurement of SAD? / 28
Table 3: Seasonal pattern assessment questionnaire / 29
Is SAD distinct from other mood/affective disorders? / 33
What is the differential diagnosis for SAD? / 35

Conclusions: diagnosis of SAD /36

Part 2: Epidemiology / 36

What is the prevalence of SAD? / 36
What is the female-to-male ratio in people with SAD? / 39
What is the prevalence of SAD with respect to age? / 39

*Table 4: Lifetime prevalence estimates of DSM-III-R major depression with a seasonal pattern, using successively more strict criteria / 39*

What is the effect of time of year of interview on prevalence? / 40
Does latitude influence the prevalence estimate of SAD? /40
What is the impact of other demographic variables on the prevalence of SAD? / 40

Conclusions: epidemiology of SAD / 41

Part 3: Etiology and Pathophysiology / 41

Is SAD simply due to decreased light? / 41
What is the role of melatonin in SAD? / 42
What is the role of circadian rhythm disturbance in SAD? / 43
Is the eye involved in the etiology of SAD? / 45
Which neurotransmitters contribute to SAD? / 46
Are there genetic vulnerability or protective factors in SAD? / 47
What are the hormonal and metabolic changes in SAD? / 48
Are there psychological and/or personality factors associated with SAD? / 49

Conclusions: etiology and pathophysiology of SAD / 51

**Section 2: Light Treatment** / 64

*(edited by Raymond W. Lam)*

Raymond W. Lam, Edwin M. Tam, Christopher P. Gorman, Carl Blashko, Rudradeo C. Bowen, Rachel L. Morehouse, and Gary Hasey

What is light therapy? / 64
Is light therapy an effective treatment for SAD? / 65
What light devices are available? / 65

Recommendations: light devices / 67
Contents

What are the relevant parameters of light therapy? / 67
What “dose” of light therapy should be used? / 68
Should light therapy be given in the morning, evening, or both? / 69
What wavelength of light should be used? / 70
What constitutes an adequate length of time for a trial of light therapy? / 71
Are there predictors of outcome for light therapy? / 71
How do patients obtain light devices? / 72
What practical tips are there for using light therapy? / 72
What are the side effects of light therapy? / 73
Can light therapy produce ocular damage? / 73
Table 5: Reported side effects of light therapy for SAD / 74
What ophthalmological screening should be done in patients prescribed light therapy? / 75

Recommendations: parameters for light therapy / 76
Can light therapy be used in children? / 76
How does light therapy affect people without SAD? / 77
Is light therapy effective for nonseasonal depression? / 77
What other psychiatric disorders can be treated with light therapy? / 78
How can light therapy be used to treat other circadian disorders? / 78

Recommendations: light therapy for other disorders / 79
What novel treatments have been studied in SAD? / 79

Recommendations: novel treatments for SAD / 80
What is an appropriate placebo condition for light-treatment studies? / 80

Recommendation: placebo response / 81

Section 3: Medication Treatment / 89
(edited by Anthony J. Levitt)
Anthony J. Levitt, Raymond W. Lam, and A.-Missagh Ghadirian

Are antidepressants effective in the treatment of SAD? / 89
What is the usual effective dose of antidepressants in SAD? / 91
What are the side effects of antidepressants? / 92
How long should an acute trial of antidepressant last? / 92
Have other medications been studied in the treatment of SAD? / 93
Recommendations: medication treatment / 94

Section 4: Management Issues / 96
(edited by Raymond W. Lam)
Raymond W. Lam, Anthony J. Levitt, Robert P. Kraus, Rudradeo C. Bowen, Rachel L. Morehouse, Gary Hasey, and Robert D. Levitan

How do you choose between light therapy and medications? / 96
Table 6: Factors to consider in the choice between light therapy and antidepressant medications as first-line treatments / 97
When should you combine medications and light therapy? / 99
Recommendations: light therapy, antidepressants, or both? / 100
How long is an adequate trial of light therapy or medications? / 101
How long should a patient with SAD be treated within a season? / 101
Should treatment continue throughout the summer? / 102
When should treatment be restarted in the year following successful treatment? / 103
Recommendations: length of treatment / 104
How do you manage comorbidity? / 104
Recommendations: managing comorbidity / 107
Can psychotherapy serve as an adjunct to light therapy or medications for SAD? / 107
How do you manage patients who do not respond to treatment? / 108
Recommendations: managing limited treatment response / 111

Resources / 115
Bibliography / 117
Index / 155
<table>
<thead>
<tr>
<th>Name</th>
<th>Affiliation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Raymond W. Lam, MD, FRCPC</td>
<td>Professor and Head, Division of Mood Disorders, Department of Psychiatry, University of British Columbia; Medical Director, Mood Disorders Program, UBC Hospital, Vancouver, BC</td>
</tr>
<tr>
<td>Anthony J. Levitt, MBBS, FRCPC</td>
<td>Associate Professor, Departments of Psychiatry and Nutrition, University of Toronto; Head, Mood Disorders Program, Sunnybrook Health Sciences Centre, Toronto, ON</td>
</tr>
<tr>
<td>Carl Blashko, MD, FRCPC</td>
<td>Clinical Professor, Department of Psychiatry, University of Alberta; Staff Psychiatrist, Grey Nuns Hospital, Edmonton, AB</td>
</tr>
<tr>
<td>Rudradeo C. Bowen, MD, FRCPC</td>
<td>Professor of Psychiatry, University of Saskatchewan; Director, Anxiety and Mood Disorders Program, Saskatoon District Health, Saskatoon, SK</td>
</tr>
<tr>
<td>Murray W. Enns, MD, FRCPC</td>
<td>Associate Professor, Department of Psychiatry, University of Manitoba; Medical Director, Mood Disorders Program, Health Sciences Centre, Winnipeg, MB</td>
</tr>
<tr>
<td>A.-Missagh Ghadirian, MD, FRCPC</td>
<td>Professor of Psychiatry, McGill University; Director of Mood Disorders Clinic, Royal Victoria Hospital, McGill University Health Centre, Montreal, PQ</td>
</tr>
<tr>
<td>Christopher P. Gorman, MD, FRCPC</td>
<td>Clinical Associate Professor, Department of Psychiatry, University of Calgary; Staff Psychiatrist, Foothills Medical Centre, Calgary, AB</td>
</tr>
</tbody>
</table>
Gary M. Hasey, Assistant Professor, Department of Psychiatry, MD, MSc, FRCPC
McMaster University; Clinical Director, Regional Mood Disorders Program, Hamilton Psychiatric Hospital, Hamilton, ON

Robert P. Kraus, Associate Professor (part time), MD, FRCPC
Department of Psychiatry and Behavioural Neurosciences, McMaster University; Medical Program Manager for Mental Health, The St. Catharines General Hospital, St. Catharines, ON

Robert D. Levitan, Assistant Professor of Psychiatry, University of MD, FRCPC
Toronto; Research Head, Depression Clinic, Centre for Addiction and Mental Health, Toronto, ON

Rachel L. Morehouse, Associate Professor, Department of Psychiatry, MD, FRCPC
Dalhousie University; Director, Somnology Clinic, St. John Regional Hospital, St. John, NB

Adam Moscovitch, Medical Director, Canadian Sleep Institute, MD, FRCPC
Calgary, AB

Dan Oren, Associate Professor of Psychiatry, Yale University: Research Associate, US Department MD of Veterans Affairs, West Haven, CT

Edwin M. Tam, Clinical Assistant Professor, Division of Mood MD, FRCPC Disorders, Department of Psychiatry, University of British Columbia; Staff Psychiatrist, UBC Hospital, Vancouver, BC

Michael Terman, Professor, Department of Psychiatry, Columbia MD, PhD University; Director, Clinical Chronobiology Program, New York State Psychiatric Institute, New York, NY

Anna Wirz-Justice, Professor, University of Basel Medical School; PhD Head, Chronobiology and Sleep Laboratory, Psychiatric University Clinic, Basel, Switzerland
## Abbreviations Used

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>5-HT</td>
<td>5 hydroxytryptamine (serotonin)</td>
</tr>
<tr>
<td>ACTH</td>
<td>adrenocorticotropic hormone</td>
</tr>
<tr>
<td>BDI</td>
<td>Beck Depression Inventory</td>
</tr>
<tr>
<td>BDI-II</td>
<td>Beck Depression Inventory, version II</td>
</tr>
<tr>
<td>CBT</td>
<td>cognitive behavioural therapy</td>
</tr>
<tr>
<td>CES-D</td>
<td>Centres for Epidemiological Studies – Depression</td>
</tr>
<tr>
<td>CIDI</td>
<td>Composite International Diagnostic Interview</td>
</tr>
<tr>
<td>CRH</td>
<td>corticotropin-releasing hormone</td>
</tr>
<tr>
<td>DSM-III-R</td>
<td>Diagnostic and Statistical Manual for Mental Disorders, 3rd edition, revised</td>
</tr>
<tr>
<td>DSM-IV</td>
<td>Diagnostic and Statistical Manual for Mental Disorders, 4th edition</td>
</tr>
<tr>
<td>EOG</td>
<td>electrooculography</td>
</tr>
<tr>
<td>GSS</td>
<td>Global Seasonality Score</td>
</tr>
<tr>
<td>HAM-D</td>
<td>Hamilton Depression Rating Scale</td>
</tr>
<tr>
<td>HDRS</td>
<td>Hamilton Depression Rating Scale</td>
</tr>
<tr>
<td>HMU</td>
<td>head mounted unit</td>
</tr>
<tr>
<td>HPA</td>
<td>hypothalamic-pituitary-adrenal</td>
</tr>
<tr>
<td>ICD-10</td>
<td>International Classification of Diseases, 10th edition</td>
</tr>
<tr>
<td>IOP</td>
<td>intraocular pressure</td>
</tr>
<tr>
<td>IPT</td>
<td>interpersonal psychotherapy</td>
</tr>
<tr>
<td>ISV</td>
<td>Inventory of Seasonal Variation</td>
</tr>
<tr>
<td>LED</td>
<td>light emitting diode</td>
</tr>
<tr>
<td>m-CPP</td>
<td>m-chlorophenylpiperazine</td>
</tr>
<tr>
<td>MDD</td>
<td>major depressive disorder</td>
</tr>
<tr>
<td>MDE</td>
<td>major depressive episode</td>
</tr>
<tr>
<td>MeSH</td>
<td>Medical Subject Headings</td>
</tr>
<tr>
<td>NIH</td>
<td>National Institutes of Health</td>
</tr>
<tr>
<td>NIMH</td>
<td>National Institute of Mental Health</td>
</tr>
<tr>
<td>PMDD</td>
<td>premenstrual dysphoric disorder</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Description</td>
</tr>
<tr>
<td>--------------</td>
<td>--------------------------------------------------</td>
</tr>
<tr>
<td>RCT</td>
<td>randomized controlled trial</td>
</tr>
<tr>
<td>RDC</td>
<td>Research Diagnostic Criteria</td>
</tr>
<tr>
<td>RMR</td>
<td>resting metabolic rate</td>
</tr>
<tr>
<td>SAD</td>
<td>seasonal affective disorder</td>
</tr>
<tr>
<td>SCN</td>
<td>suprachiasmatic nucleus</td>
</tr>
<tr>
<td>SIGH-SAD</td>
<td>Structured Interview Guide for the Hamilton Depression Rating Scale, SAD version</td>
</tr>
<tr>
<td>SP</td>
<td>seasonal pattern</td>
</tr>
<tr>
<td>SPAQ</td>
<td>Seasonal Pattern Assessment Questionnaire</td>
</tr>
<tr>
<td>S-SAD</td>
<td>subsyndromal seasonal affective disorder</td>
</tr>
<tr>
<td>SSRI</td>
<td>selective serotonin reuptake inhibitor</td>
</tr>
<tr>
<td>T3</td>
<td>triiodothyronine</td>
</tr>
<tr>
<td>T4</td>
<td>thyroxine</td>
</tr>
<tr>
<td>TRH</td>
<td>thyroid releasing hormone</td>
</tr>
<tr>
<td>TSH</td>
<td>thyroid stimulating hormone</td>
</tr>
</tbody>
</table>
The Book of Ecclesiastes records that “there is nothing new under the sun” (1:9). The story of winter depression (seasonal affective disorder) is eloquent testimony to this ancient dictum. The struggle to treat the sometimes disabling symptoms of this disorder occupies the minds of some of today’s best psychiatrists and psychologists, much as it caught the attention of physicians as ancient as Hippocrates almost two and a half millennia ago. A record of Greco-Roman physicians treating depression and lethargy with sunlight dates back to the second century (Adams, 1856; Aurelianus, 1950). Post-Enlightenment descriptions of seasonal depression appeared in the medical literature sporadically during the past two centuries (Oren and Rosenthal, 1992; Wehr, 1989b). But such reports failed to stimulate a coherent line of scientific investigation of the clinical phenomena or the novel treatment.

Beginning in the late 1970s, however, a number of investigators developed an insight that disorders of the biological clock and the processing of light thought important to regulate that clock might play etiological or at least pathophysiological roles in some psychiatric illnesses. In 1981, Daniel F. Kripke published the first modern paper demonstrating that some patients with depression had clinical responses to bright-light treatment. What had probably played the catalytic role in bringing an obscure field of science to the pages of Science, however, was a groundbreaking paper in 1980 by Alfred J. Lewy and his colleagues at the National Institute of Mental Health (NIMH) in Bethesda, Maryland, USA. Demonstrating that bright light has the capacity to suppress melatonin production in humans, these researchers crossed a paradigmatic barrier and established that humans, like virtually every other animal ever studied, possess a functional “switch” that is acutely sensitive to bright light. In short order, Herbert A. Kern became aware of this work and approached the NIMH researchers with his own record of
recurrent winter depressions and the hope that their work with light might successfully treat his depression. The results were dramatic (Lewy et al., 1982). NIMH researcher Norman E. Rosenthal and colleagues’ landmark papers demonstrating that winter depression or “seasonal affective disorder” can be considered a distinct subtype of major depression and that light therapy is an effective treatment for the disorder quickly attracted the attention of the media, patients, and researchers across the globe (Rosenthal et al., 1984a; 1985).

In the subsequent decade and a half, the number of papers about the subject has steadily increased. As a crude measure of this growth, a survey by this author of Medline-cited papers on the topics of “seasons” or “seasonal affective disorder” and “depression” shows that nine were published in 1985 whereas 45 were published in 1997! It would be conservative to state that by 1998 more than 1,000 patients worldwide had participated in controlled clinical trials of light or antidepressant medication therapy for the disorder. The great interest in the field led to the formation of the Society for Light Treatment and Biological Rhythms, an international academic and clinical society devoted partly to the understanding and treatment of winter depression.

We are now at an exciting threshold in the study of the phenomenon. Controversies that have beset the field have achieved some resolution or at least been addressed to allow new formulations of investigative directions. Perhaps the primary controversy has been whether light therapy is an effective treatment or just a placebo treatment for the disorder. Landmark papers just published by Michael Terman et al. (1998), Alfred J. Lewy et al. (1998b), and Charmane I. Eastman et al. (1998) take major steps toward putting this critical question to rest. Although the question still remains whether winter depression is a disorder whose etiology and treatment rest in the domain of delayed biological rhythms that are advanced by light or other interventions, much of the literature supports the basic elements of the circadian “phase-shift” hypothesis (Lewy et al., 1987a).

The molecular basis of the syndrome remains a mystery. While the work of Raymond W. Lam et al. (1996b) and others clearly demonstrates that serotonin regulation plays a role in the syndrome, other neurotransmitters may also play critical roles. The failure by basic and clinical researchers to establish which photoreceptors or photoreceptor molecules mediate light’s effects in the syndrome led this author to propose that humoral factors may act as photoreceptors and transduce the antidepressant and rhythm-shifting effects of light (Oren et al., 1996; Oren,
1997). Although such a theoretical model remains to be proved or disproved, publication of the work of Scott S. Campbell and Patricia J. Murphy (1998), demonstrating that light applied to the popliteal skin (behind the knees) has the capacity to reset circadian rhythms in humans, is consistent with this construct.

Similar to the pace in so many areas of medicine, what we have learned in the past 15 years about this disorder surely equals or exceeds what was learned in the 1,500 years before. In this context, these consensus guidelines assembled by Raymond W. Lam and Anthony J. Levitt and their Canadian colleagues mark a culmination and summation of an era. The documents that follow are based on careful assessment of the strengths and weaknesses of virtually every known study ever conducted for the treatment of winter depression. By summarizing a world literature demonstrating the efficacy of light therapy, and now a pharmacotherapy for winter depression, these guidelines will surely reach landmark status in their own right. Having had the privilege to attend the authors’ first consensus-gathering meeting on the subject, I can bear witness to their thorough review and their tough-minded insistence on valuing sound scientific data, while being appropriately cautious about rubber-stamping clinical impressions gathered without controlled trials. These consensus guidelines will surely be of value to Canadian health care providers and to clinicians the world over, for there is simply nothing to match this accomplishment.

I expect that in another 15 years Lam and Levitt will wish to reconvene their panel to integrate the results of studies still to come. If scientific interest remains at its current level, by then we will know not just what time of day is best to treat winter depression with light but also why. We will know not just the value of antidepressants for the disorder but also the specific neurotransmitters that are regulated to have the antidepressant effect. More exotic treatments currently under study will also emerge as either dramatic successes or disappointing failures. In the interim, any clinician interested in offering a patient with winter depression the best that medical science has to offer will surely be well advised to turn to these guidelines.

References


Terman M, Terman JS, Ross DC. A controlled trial of timed bright light and negative air ionization for treatment of winter depression. Arch Gen Psychiatry 1998; 55:875-82.

INTRODUCTION

Raymond W. Lam, MD, FRCP
Professor and Head, Division of Mood Disorders
Department of Psychiatry, University of British Columbia

Anthony J. Levitt, MBBS, FRCP
Associate Professor, Departments of Psychiatry
and Nutritional Sciences, University of Toronto

In 1994, we organized a Canadian Consensus Group on seasonal affective disorder (SAD) to attend a workshop that was funded by grants from the Medical Research Council of Canada and Health and Welfare Canada. Clinicians-researchers from the major academic centres in Canada were invited to the Clarke Institute of Psychiatry in Toronto to present their work, develop consensus on the diagnosis and treatment of SAD, and discuss directions for future research. Although a major review of the literature arose from this workshop (Tam et al., 1995), the consensus then was that there were too few controlled studies to formulate treatment guidelines for SAD.

By 1998, the situation had changed. Several randomized, large-sample, placebo-controlled studies of light therapy and antidepressant therapy have since been published, and there has been new research on the diagnosis, epidemiology, and pathophysiology of SAD. Much of this research has been conducted in Canada, where SAD carries a significant burden for the health care system. We decided that it was timely to reconvene the Canadian Consensus Group on SAD to develop expert consensus guidelines for the treatment of SAD. Dr. Dan Oren of Yale University was invited to participate as an external consultant.

The purpose of the consensus guidelines project was to systematically review all available evidence regarding the diagnosis, clinical features, epidemiology, pathophysiology, and treatment of SAD and to produce a series of recommendations that were clinically and scientifically meaningful. The target audience for the guidelines included family physicians, psychiatrists, psychologists, nurses, and other health professionals who treat depression and SAD.

A rigorous method to reach consensus was adopted. A Medline search (updated as of June 1, 1999) was conducted for all indexed articles using MeSH and text word searches for papers relating to SAD, seasonal
depression, and light therapy. Additionally, consensus panel members reviewed the bibliography for omissions, and researchers in the Society for Light Treatment and Biological Rhythms were canvassed for studies completed or in press. Eventually, over 650 articles were reviewed.

Two consensus panel members were assigned to independently review each topic using level of evidence criteria (Steering Committee, 1998) and to summarize their findings in evidence tables. These levels of evidence are defined as follows:

- **Level 1** = randomized, controlled trials (RCTs) with sufficient numbers or good-quality meta-analyses based on RCTs
- **Level 2** = RCTs with smaller numbers (therefore insufficient power or limited generalizability of results)
- **Level 3** = Non-randomized, controlled or cohort studies, case series, case-controlled studies or high-quality retrospective studies
- **Level 4** = evidence based on the published opinions of expert committees, such as consensus/guidelines committees
- **Level 5** = evidence that expresses the opinions of the committee members who have reviewed the literature and guidelines, following discussion with peers (note that, following the consensus process, level 5 evidence becomes level 4 evidence).

The reports from the reviewers were then presented during a consensus meeting held during a joint meeting of the Society for Light Treatment and Biological Rhythms and the Society for Research in Biological Rhythms, at Amelia Island, Florida, in June 1998. Consensus on controversial areas was obtained, and a draft guidelines document was completed. In September 1998, the draft guidelines were ratified and adopted at a consensus meeting held during the annual meeting of the Canadian Psychiatric Association in Halifax, Nova Scotia. The draft guidelines were then reviewed by Dr. Dan Oren, Dr. Michael Terman at Columbia University in New York, and Dr. Anna Wirz-Justice in Basel, Switzerland.

In summary, these guidelines were arrived at by consensus and have undergone both internal review by the 14 members of the Canadian Consensus Group and by international consultants. Recommendations are based on the scientific literature and on the clinical experience of the consensus panel. To make the guidelines more accessible to the practicing clinician, we chose to present the findings in a question-and-answer format followed by conclusions or recommendations. The levels
of evidence on which the recommendations are based are listed after each recommendation, so that areas where data are limited are apparent. There are sections on diagnosis, epidemiology, pathophysiology, light treatment, medication treatment, and management issues. Finally, a resource list and a full bibliography are included in the appendices. Note that we have used the term “SAD” in this document to indicate winter depression, and “light therapy” is used as per consensus in the field, to distinguish light therapy for SAD from other types of phototherapy (e.g., for hyperbilirubinemia).

Dissemination of clinical guidelines is also an important issue. An executive summary of these guidelines was completed to provide a quick reference for the clinician. This summary was published as a supplement to the Canadian Journal of Diagnosis (Lam and Levitt, 1998) to ensure the widest distribution of this information to physicians across Canada. The summary is also available on the Internet (see Resources).

These guidelines would not have been possible without the hard work of many people. We want to thank all the members of the Canadian Consensus Group on SAD and our external consultants for their dedication to the tight deadlines that we imposed. Thanks, too, to Arvinder Grewal and Julie Thomson for their management and secretarial support. We also thank Pfizer Canada for providing an unrestricted educational grant in support of these guidelines and Steven Kost for his encouragement throughout the project.

We hope that the information presented in these guidelines will assist clinicians to better identify patients with SAD and to manage the disorder more effectively. We also hope that the guidelines will help physicians to answer some of the many questions that patients and family members ask about SAD.

References